Faron Pharmaceuticals Ltd has appointed Marie-Louise Fjällskog as chief medical officer to oversee development of bexmarilimab, a potential monotherapy for patients with solid tumours. Dr Fjällskog was previously CMO at Sensei Biotherapeutics Inc and will be based in Boston, US. Prior to this, she led clinical development at Merus NV of the Netherlands and Infinity Pharmaceuticals Inc in Cambridge, US. She has also headed clinical programmes at the Novartis Institutes for Biomedical Research.
Dr Fjällskog holds both a PhD and MD from Uppsala University in Sweden.
Faron announced the appointment on 3 January 2022.
Copyright 2022 Evernow Publishing Ltd